Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.60 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13638129 | 0.85 | KMT2A (0.71) | KMT2AKDM4EMEN1SIGMAR1MC4R | |
| SCHEMBL16226234 | 0.85 | KMT2A (0.71) | KMT2AKDM4EMEN1SIGMAR1MC4R | |
| SCHEMBL3312142 | 0.83 | KMT2A (0.69) | KMT2AKDM4EMEN1SIGMAR1MC4R | |
| SCHEMBL3260289 | 0.83 | SIGMAR1 (0.64) | KMT2AKDM4EMEN1SIGMAR1MC4R | |
| SCHEMBL6742979 | 0.82 | SIGMAR1 (0.69) | KMT2AKDM4EMEN1SIGMAR1MC4R | |
| SCHEMBL278653 | 0.82 | SIGMAR1 (0.69) | KMT2AKDM4EMEN1SIGMAR1MC4R | |
| SCHEMBL14407770 | 0.82 | SIGMAR1 (0.69) | KMT2AKDM4EMEN1SIGMAR1MC4R | |
| SCHEMBL16226336 | 0.82 | KMT2A (1.00) | KMT2AKDM4EMEN1SIGMAR1MC4R | |
| SCHEMBL16226907 | 0.82 | KMT2A (1.00) | KMT2AKDM4EMEN1SIGMAR1MC4R | |
| SCHEMBL16227228 | 0.82 | KMT2A (1.00) | KMT2AKDM4EMEN1SIGMAR1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, PLK2, PNCK | KMT2A 2261/4885KDM4E 1351/4885MEN1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.